Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT03713099 Not yet recruiting - Lung Cancer Clinical Trials

NEUWAVE Flexible Probe Study #2

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Patients with medically inoperable and operable secondary soft tissue lesion(s) of the lung will have transbronchial microwave ablation performed using cone beam CT for probe guidance and confirmation.

NCT ID: NCT03711422 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Start date: October 2018
Phase: Phase 1
Study type: Interventional

Brain metastases occurs in up to 50% of patients with EGFR mutant NSCLC. Leptomeningeal disease is a subset of patients with brain metastases for which there remains an unmet need. This trial aims to evaluate the role of two dosing schedules of afatinib in management of leptomeningeal disease in EGFR mutant NSCLC, specifically to determine Central Nervous System (CNS) penetration of afatinib, as well as clinical activity. Patients will start on daily dosing initially followed by pulsed intermittent dosing should we observe no clinical activity. A secondary objective is to identify the resistance spectrum in leptomeningeal disease. It is anticipated that optimal dosing schedule of afatinib e.g. pulsed dosing may improve CNS disease control.

NCT ID: NCT03710629 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes

Start date: July 1, 2018
Phase:
Study type: Observational

A single-center, non-interventional prospective observational study in the NSCLC patients with different driver genes

NCT ID: NCT03710616 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals

Start date: March 24, 2018
Phase:
Study type: Observational

The real-world study was designed to explore recurrence/metastases of the patients with non-small cell lung cancer as measured by patient survivals and the impact factors of patient survivals.

NCT ID: NCT03708328 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Start date: October 15, 2018
Phase: Phase 1
Study type: Interventional

This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent RO7121661, an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. The study consists of 2 parts: Dose Escalation (Parts A1 and A2) and Dose Expansion (Parts B1, B2, and B3). The Dose Escalation part will be conducted first to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) based on safety, tolerability, pharmacokinetic, and/or the pharmacodynamic profile of escalating doses of RO7121661. The Dose Expansion part will enroll tumor-specific cohorts to evaluate anti-tumor activity of the MTD and/or RDE of RO7121661 from Part A (Q2W and if available, Q3W) and to confirm safety and tolerability in participants with selected tumor types.

NCT ID: NCT03706625 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment

IDeATIon
Start date: October 2018
Phase:
Study type: Observational

The explosion of novel therapies targeting tumor mutations or immune molecules requests to define or better characterize the mutational profiles of tumors that are none or insufficiently explored so far. This is particularly the case for tumors arising in immune-suppressed individuals or environments which have been poorly, if any, analyzed so far with modern molecular methods. The goal of the translational research program, Ideation, is to define novel biomarkers such as the tumor mutational profiling and immunomutanome in such contexts and to compare the results obtained to those observed in immune competent individuals. In addition, this approach will allow to characterize novel key non-invasive diagnostic and prognostic biomarkers such as circulating tumoral DNA and cells. Altogether results will provide novel biomarkers to better adapt therapeutic strategies in these cancers, to monitor response to treatment as well as to define new molecular targets of potential therapeutic strategies.

NCT ID: NCT03704688 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Start date: October 9, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.

NCT ID: NCT03700437 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC)

Start date: October 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to learn the effects of fasting on cancer cells during chemo-immunotherapy.

NCT ID: NCT03699033 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer

Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

Single center, single arm, Phase II study designed to evaluate the feasibility of hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with 4D PET/CT-based radiation treatment planning and concurrent carboplatin and paclitaxel in Stage IIIA or Stage IIIB NSCLC subjects.

NCT ID: NCT03689855 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

RamAtezo-1
Start date: January 31, 2019
Phase: Phase 2
Study type: Interventional

Data suggests that combining ramucirumab with immunotherapy in non-small cell lung cancer (NSCLC) patients who have previously received immune checkpoint blockers (ICBs) may be more effective than traditional therapy. The investigators propose a pilot study to test the combination of ramucirumab and atezolizumab in patients with advanced-stage NSCLC patients previously treated with ICB.